

CIN: L24231MH1992PLC323914

(Formerly known as Generic Pharmasec Limited)

Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises Co-Operative Society Ltd., Akurli Road, Kandivali (East), Mumbai, Maharashtra, 400101

+91-86555 50242

compliance@genpharmasec.com info@genpharmasec.com

www.genpharmasec.com

Date: 14th July, 2023

BSE Limited The Compliance Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001.

Scrip Code: 531592

Sub : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 i.e. Intimation of incorporation of Subsidiary Company.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we wish to inform you that the Company has Incorporated a foreign subsidiary namely "GENPHARMASEC MIDDLE EAST DMCC"

The details as required under Regulation 30 of the Listing Regulations read with SEBI circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached herewith as Annexure - I.

Kindly take the same on records for your perusal.

Thanking you,

For and behalf of the Bourdalling

Genpharmasec Limited HETA

DEEPAK SHAH

Oate: 2023.07.14

Heta Shah Company Secretary & Compliance

ICSI Membership Number . A697+9

Enclosure: a/a



CIN: L24231MH1992PLC323914

(Formerly known as Generic Pharmasec Limited)

Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101

+91-86555 50242

compliance@genpharmasec.com info@genpharmasec.com

www.genpharmasec.com

## ANNEXURE - I

Required disclosures in respect of Incorporation of subsidiary company owned, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015:

Sr. No.	Particulars	Remarks
1	Name of the target entity, details in brief such as size, turnover, etc.;	Genpharmasec Middle East DMCC The Company is newly incorporated.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The Company has made an Initial Subscription in the Company.  Further, Mr. Rajesh Sadhwani, Promoter & Non-Executive Director of the Company, is the shareholder of the subsidiary Company as per details mentioned below.  Number Of Shares: 24 Type Of Shares: Ordinary Shares Value Per Share: AED 1000.00/- Percentage: 48%
3	Industry to which the entity being acquired belongs;	The Business Activity which the company Propose is : Retail Trading
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The objects for which the Company has been established are:  Medical, Surgical Equipment & Instruments Trading.  Medical, Surgical Articles & Requisites Trading Medical Gas Trading  Food Supplements Trading  Trading in Medicines (Outside UAE) (DMCC)  Trading in Pharmaceutical Products (Outside UAE) (DMCC)
5	Brief details of any governmental or regulatory approvals required for the acquisition;	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
6	indicative time period for completion of the acquisition;	N
7	Nature of consideration - whether cash or share swap and details of the same;	
8	Cost of acquisition or the price at which the shares are acquired;	
9	Percentage of shareholding / control acquired and / or number of shares acquired;	
10	Brief background about the entity	The Company is newly incorporated